Clinical Trial Update: Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer [Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 2 study evaluating imatinib mesylate in combination with docetaxel for advanced, platinum-refractor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Docetaxel (Taxotere) (docetaxel)
• Imatinib Mesylate (Gleevec) (Imatinib mesylate)

Snippet

Sponsor: Daniela Matei, MD | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED